Quick Answer
MBX Biosciences, Inc. reported Diluted EPS of $2.38 per share (loss) for fiscal year 2025.
MBX Biosciences, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$2.38 | +59.1% |
| 2024 | -$5.82 | +81.8% |
| 2023 | -$31.96 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.63 | +77.3% | -8.6% |
| June 30, 2025 | -$0.58 | +95.4% | +18.3% |
| March 31, 2025 | -$0.71 | +93.1% | +74.5% |
| September 30, 2024 | -$2.78 | +70.4% | +78.0% |
| June 30, 2024 | -$12.62 | — | -23.0% |
| March 31, 2024 | -$10.26 | — | -9.1% |
| September 30, 2023 | -$9.40 | — | — |
- MBX Biosciences, Inc. showed an increase of +59.1% in Diluted EPS compared to the prior fiscal year.
- Over the 2023–2025 period, MBX Biosciences, Inc.’s diluted eps has grown by 92.6% (from $31.96 per share (loss) to $2.38 per share (loss)).
- The most recent figure is from MBX Biosciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: